Biogen· @biogen · X·· 2026-06-04精选AI 评分60
AI 导读
渤健宣布，美国FDA已授予其一款在研脊髓性肌萎缩症（SMA）疗法突破性疗法认定。渤健称这是其SMA管线的一项重要里程碑，更多信息见 https://bit.ly/49B9vj0。
推荐理由
渤健披露其脊髓性肌萎缩症在研疗法获FDA突破性疗法认定，读者可据此了解该管线的监管进展。
正文
#News: Today, we announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for an investigational therapy for spinal muscular atrophy (SMA). Learn more about this important milestone: https://bit.ly/49B9vj0
来源：Biogen · x.com